David A. Siegel Elevation Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 107,400 shares of ELEV stock, worth $38,664. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,400
Previous 193,100
44.38%
Holding current value
$38,664
Previous $50,000
22.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ELEV
# of Institutions
65Shares Held
32MCall Options Held
50KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.16 Million0.12% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$2.12 Million1.64% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.02 Million0.29% of portfolio
-
Black Rock Inc. New York, NY2.49MShares$896,4890.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.26MShares$812,4080.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.39M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...